First CVD outcome trial of a GLP-1 agonist finds no cardiac risk or benefit

Popular glucose-lowering drugs also show no risk of hypoglycemia or pancreatic injury, and modest benefit for weight compared to placeboOne member of a widely prescribed class of drugs used to...